Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

Presentation TCT 2025

TCT 763: Finerenone in Patients Undergoing TAVR for Nonrheumatic Aortic Stenosis: Insights from a Real-World Cohort

Presenter: Faysal Massad

October 27, 2025

News Daily News

After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes

Todd Neale

October 07, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Conference News ESC Heart Failure 2025

Finerenone May Cut Early Readmissions in HF Patients

Todd Neale

May 21, 2025

News Daily News

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Michael O'Riordan

March 03, 2025

Presentation THT 2025

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

Presenter: Carolyn Lam

February 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2025

Shelley Wood

January 31, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Daily News

Top Heart Failure News of 2024

Todd Neale

December 31, 2024

News Daily News

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

L.A. McKeown

December 13, 2024

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2024

Shelley Wood

October 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

Caitlin E. Cox

September 03, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Presentation ESC 2024

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Presenter: Muthiah Vaduganathan

September 01, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

Advertisement

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

TCT 763: Finerenone in Patients Undergoing TAVR for Nonrheumatic Aortic Stenosis: Insights from a Real-World Cohort

After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Finerenone May Cut Early Readmissions in HF Patients

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

TCTMD’s Top 10 Most Popular Stories for January 2025

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Top Heart Failure News of 2024

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

TCTMD’s Top 10 Most Popular Stories for September 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content